Temporary Scheduling of Bromazolam and Novel Benzodiazepines
The temporary scheduling of novel benzodiazepines such as bromazolam reflects regulatory efforts to address emerging abuse risks. This update highlights clinical toxicology concerns and enforcement under the Controlled Substances Act. Clinicians should…
DEA Update on Diphenidine Scheduling in Controlled Substances Act
The DEA scheduling diphenidine update reflects its placement in Schedule I due to high abuse potential and no accepted medical use. This regulatory action highlights challenges in controlling novel synthetic dissociatives. Clinicians should stay informed…
DEA Places Four Synthetic Cannabinoids in Schedule I
The Drug Enforcement Administration has placed four synthetic cannabinoids into Schedule I due to their high abuse potential and lack of accepted medical use. These DEA Schedule I synthetic cannabinoids include 4F-MDMB-BUTICA, ADB-4en-PINACA,…
DEA Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I
The U.S. Drug Enforcement Administration has placed CUMYL-PEGACLONE, a synthetic cannabinoid analog, into Schedule I of the Controlled Substances Act due to its high abuse potential and lack of accepted medical use. This CUMYL-PEGACLONE Schedule I…
DEA Places 2-Fluorodeschloroketamine in Schedule I Controlled Substances
The DEA has temporarily placed 2-fluorodeschloroketamine in Schedule I of the Controlled Substances Act, reflecting regulatory action against emerging synthetic ketamine analogs. This DEA Schedule I classification demonstrates the federal approach to…
Policy Watch: DEA Schedule I Placement of Synthetic Cannabinoids — June 08, 2026
This Policy Watch covers DEA synthetic cannabinoids schedule I placement updates for June 08, 2026. These regulatory actions affect clinical and research practices involving controlled substances. Clinicians should stay informed about these changes to…
Policy Watch: Key Synthetic Cannabinoids Schedule I Updates — June 02, 2026
This policy watch highlights synthetic cannabinoids Schedule I updates 2026 with significant clinical and regulatory implications. The DEA's recent actions classify several synthetic cannabinoids as Schedule I substances, affecting clinicians and…
US DOJ Proposes Marijuana Reclassification: Federal Policy Shift
The marijuana reclassification federal policy proposed by the DOJ marks a significant shift in cannabis regulation. This change could enable expanded medical research and improve patient access. It reflects growing acceptance of cannabis's medical use at…
Medical Marijuana Reclassified as Less Dangerous Drug – WHIO-TV
The medical marijuana rescheduling impacts are significant for clinical research and policy development. This reclassification to Schedule III removes barriers to rigorous studies. Clinicians anticipate improved evidence-based cannabis medicine as a…
U.S. Department of Justice Issues Final Order Rescheduling Medical Cannabis
The final order rescheduling medical cannabis to Schedule III marks a pivotal federal policy shift. This change removes longstanding barriers to clinical research. It enables FDA-approved studies and standardized trials to advance cannabis medicine.